FDA/CDC

FDA approves dabrafenib/trametinib for BRAF-positive anaplastic thyroid cancer


 

The Food and Drug Administration has approved dabrafenib (Tafinlar) and trametinib (Mekinist), delivered in combination, for the treatment of BRAF V600E–positive anaplastic thyroid cancer.

FDA approval was based on results from an open-label clinical trial of patients with various rare, BRAF V600E–positive cancers. In a group of 23 patients, 57% experienced a partial response and 4% experienced a full response. In the response group, nine patients had no significant tumor growth for a period of at least 6 months.

FDA icon
Dabrafenib and trametinib has been previously approved, alone and in combination, to treat BRAF V600E–positive metastatic melanoma, as well as combination therapy for BRAF V600E–positive, metastatic non–small cell lung cancer.

The most common side effects of dabrafenib/trametinib are fever, rash, chills, headache, joint pain, cough, fatigue, nausea, vomiting, diarrhea, myalgia, dry skin, decreased appetite, edema, hemorrhage, high blood pressure, and difficulty breathing. Both drugs can cause damage to developing fetuses, and women should be advised to use proper contraception.

“This approval demonstrates that targeting the same molecular pathway in diverse diseases is an effective way to expedite the development of treatments that may help more patients,” Richard Pazdur, MD, director of the FDA’s Oncology Center of Excellence, said in the press release.

Find the full press release on the FDA website.

Next Article:

   Comments ()

Recommended for You

News & Commentary

Quizzes from MD-IQ

Research Summaries from ClinicalEdge